Representative IHC images from two patients were shown in Fig. S4A. Since ORC1 contributed the biggest part to the DGRG risk score, and CRC patients with up-regulated ORC1 expression were supposed to demonstrate reduced DGRG risk scores, the present IHC results to some extent confirmed the up-regulated PD-L1 expression and therefore the potentially improved ICI therapeutic sensitivity for low risk patients, which was in consistency with the above bioinformatic analysis results. This evidence concerns the gene ORC1 and colorectal carcinoma.